What are the best treatments for Febrile infection-related epilepsy syndrome - FIRES?

TL;DR: Febrile infection-related epilepsy syndrome (FIRES) is a catastrophic form of new-onset refractory status epilepticus that is notoriously difficult to treat, often requiring a combination of high-dose intravenous anesthetic agents and immunomodulatory therapies. Because there is no single gold-standard treatment, management is highly personalized and typically involves a multidisciplinary team to address the severe, drug-resistant seizures characteristic of the syndrome.

What are the first-line and common treatments for FIRES?

Treatment for Febrile infection-related epilepsy syndrome (FIRES) is aggressive because the condition is resistant to standard anti-seizure medications. Clinicians typically initiate care in an intensive care unit (ICU) setting using high-dose intravenous anesthetics like midazolam, pentobarbital, or propofol to induce a burst-suppression pattern on EEG. Immunotherapy is also frequently utilized, including high-dose intravenous methylprednisolone, intravenous immunoglobulin (IVIG), and sometimes plasma exchange or anakinra (Kineret).

What is the role of non-pharmacological and dietary interventions?

When standard medications fail, dietary therapies are often introduced early in the acute phase of Febrile infection-related epilepsy syndrome (FIRES). The ketogenic diet (a high-fat, low-carbohydrate regimen) is the most frequently cited non-pharmacological intervention, which may show efficacy in some patients. Long-term management often includes:

• Occupational therapy to regain motor skills lost during prolonged ICU stays.


• Physical therapy to address muscle atrophy and neurological deficits.


• Speech therapy for those experiencing cognitive or swallowing difficulties.


• Neuropsychological support to manage the significant behavioral and cognitive changes common in survivors of FIRES.

Are there emerging treatments for FIRES?

Research into Febrile infection-related epilepsy syndrome (FIRES) is rapidly evolving, with current clinical interest focused on neuroinflammation. Notable areas of investigation include the use of IL-1 receptor antagonists, such as anakinra, and other targeted immunomodulators that aim to stop the "cytokine storm" hypothesized to trigger the syndrome. Participation in international registries and clinical trials is essential, as the rarity of FIRES makes large-scale randomized controlled trials difficult to conduct.

Who should be on the multidisciplinary care team?

Managing a patient with Febrile infection-related epilepsy syndrome (FIRES) requires a highly coordinated team. Essential specialists include pediatric neurologists and epileptologists, neuro-intensivists, immunologists, clinical geneticists to rule out underlying metabolic or genetic causes, and specialized rehabilitation therapists. Engaging with the 65 members of the DiseaseMaps.org community who have experience with FIRES can provide valuable peer support during this complex journey.

Next steps

• Consult a specialized neuro-epileptologist at a tertiary care center familiar with Febrile infection-related epilepsy syndrome (FIRES).


• Ensure your medical team is coordinating care across neurology, immunology, and intensive care.


• Connect with the DiseaseMaps.org community to share experiences with other families affected by this condition.


• Discuss potential clinical trial participation with your primary neurologist.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; all treatment decisions must be made in consultation with your specialized clinical care team.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Febrile infection-related epilepsy syndrome


• Orphanet: Rare epilepsy with febrile seizures


• The NORSE Institute: Research and clinical resources for FIRES


• PubMed: Recent clinical reviews on immunomodulatory therapy in refractory status epilepticus